APLS
Apellis Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +25.0% ·
share flow -3.8% ·
net new positions +20.0%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q1 2026 | 99 | +3 | 79.10M | $3.12B | +14 | −12 |
| Q4 2025 | 97 | +1 | 73.39M | $1.84B | +2 | — |
| Q3 2025 | 19 | +1 | 50.24M | $1.14B | +1 | −1 |
| Q2 2025 | 16 | +2 | 43.69M | $756.24M | +2 | — |
| Q1 2025 | 11 | -2 | 24.93M | $545.30M | +1 | −3 |
| Q4 2024 | 13 | +2 | 23.82M | $760.24M | +3 | −1 |
| Q3 2024 | 10 | +2 | 20.37M | $587.46M | +2 | — |
| Q2 2024 | 8 | — | 21.17M | $811.69M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 15.57M | -5.0% | $448.95M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 15.57M | -5.0% | $448.95M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 3 | Wellington Management ✦ | 15.57M | -5.0% | $448.95M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 15.57M | -5.0% | $448.95M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 15.57M | -5.0% | $448.95M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 15.57M | -5.0% | $448.95M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 1.81M | +1.3% | $52.23M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 1.81M | +1.3% | $52.23M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Norges Bank ✦ (passive) | 1.07M | -1.1% | $30.79M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 817.26K | +231.0% | $23.57M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 817.26K | +231.0% | $23.57M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 817.26K | +231.0% | $23.57M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 378.46K | -70.3% | $10.91M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 378.46K | -70.3% | $10.91M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 372.33K | New | $10.74M | 0.0% | New | 1 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 198.13K | +28.8% | $5.71M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 198.13K | +28.8% | $5.71M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | Millennium Management ✦ | 77.39K | -62.4% | $2.23M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 58.78K | +113.4% | $1.70M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 20 | Marshall Wace ✦ | 21.79K | New | $628,424 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $10.74M | 0.0% |
| Marshall Wace | $628,424 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 320 holders, 137.95M shares, $5.43B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.